Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof
The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.
1. A crystalline form CS1 of N-[(1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl]glycine, wherein the X-ray powder diffraction pattern of said crystalline form shows characteristic peaks at 2theta values of 6.4°±0.2°, 7.5°±0.2°, and 7.9°±0.2° using CuKα radiation.
2. The crystalline form CS1 according to claim 1 , wherein the X-ray powder diffraction pattern shows one or more characteristic peaks at 2theta values of 17.2°±0.2°, 21.0°±0.2°, 24.0°±0.2% and 19.3°±0.2° using CuKα radiation.
3. A process for preparing crystalline form CS1 of N-[( 1 , 3 -dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl]glycine, wherein the process comprises:
(1) dissolving N-[(1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl]glycine into a solvent selected from the group consisting of a cyclic ether and a ketone to obtain a solution, wherein said cyclic ether is tetrahydrofuran; said ketone is acetone, methyl isobutyl ketone, or a mixture thereof, evaporating the obtained solution at 10-50° C. for crystallization to obtain crystalline form CS1; or
(2) dissolving N-[(1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl]glycine into 1,4-dioxane, adding water for crystallization, separating and drying to obtain crystalline form CS1.
4. The process for preparing crystalline form CS1 according to claim 3 , wherein in method (1), said evaporation temperature is room temperature or 50° C.; in method (2), said crystallization time is 0.5-24 h.
5. The process for preparing crystalline form CS1 according to claim 4 , wherein in method (1), said ketone is acetone or methyl isobutyl ketone; in method (2), said crystallization time is 2 h.
6. A crystalline form CS9 of N-[(1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl]glycine, wherein the X-ray powder diffraction pattern of said crystalline form shows characteristic peaks at 2theta values of 4.6°±0.2°, 6.6°±0.2°, and 21.1°±0.2° using CuKα radiation.
7. The crystalline form CS9 according to claim 6 , wherein the X-ray powder diffraction pattern shows one or more characteristic peaks at 2theta values of 9.4°±0.2°, 20.2°±0.2°, and 24.2°±0.2° using CuKα radiation.
8. A process for preparing crystalline form CS9 of N-[(1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl]glycine, wherein the process comprises:
(1) dissolving N-[(1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl]glycine into methyl tert-butyl ether and adding a polymer mixture to obtain a solution, wherein said polymer mixture is composed of polycaprolactone, polyoxyethylene, polymethyl methacrylate, hydroxyethyl cellulose, and sodium alginate of equal mass, evaporating the solution at 10-70° C. for crystallization; or
(2) dissolving N-[(1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl]glycine into a solvent mixture of an ester and an alcohol to obtain a solution, wherein said ester is ethyl acetate; said alcohol is ethanol; and volume ratio of said ester and said alcohol is 1:10-10:1, and evaporating the solution at 10-70° C. for crystallization.
9. The process for preparing crystalline form CS9 according to claim 8 , wherein in method (1), said evaporation temperature is 50° C.; in method (2), said evaporating temperature is 50° C.
10. The process for preparing crystalline form CS9 according to claim 9 , wherein in method (2), said volume ratio of said ester and said alcohol is 1:1.
11. A pharmaceutical composition, wherein said pharmaceutical composition comprises a therapeutically effective amount of the crystalline form CS1 according to claim 1 , and pharmaceutically acceptable carriers, diluents or excipients.
12. A method of treating anemia comprising administering to a subject in need thereof a therapeutically effective amount of the crystalline form CS1 according to claim 1 .
13. A pharmaceutical composition, wherein said pharmaceutical composition comprises a therapeutically effective amount of the crystalline form CS9 according to claim 6 , and pharmaceutically acceptable carriers, diluents or excipients.
14. A method of treating anemia, comprising administering to a subject in need thereof a therapeutically effective amount of the crystalline form CS9 according to claim 6 .
15. The method of treating anemia according to claim 12 , where the subject is a human.
16. The method of treating anemia according to claim 14 , where the subject is a human.